KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Acadia Pharmaceuticals (ACAD) Receivables - Other (2016 - 2025)

Acadia Pharmaceuticals has reported Receivables - Other over the past 13 years, most recently at $26.8 million for Q4 2025.

  • Quarterly results put Receivables - Other at $26.8 million for Q4 2025, up 349.53% from a year ago — trailing twelve months through Dec 2025 was $26.8 million (up 349.53% YoY), and the annual figure for FY2025 was $26.8 million, up 349.53%.
  • Receivables - Other for Q4 2025 was $26.8 million at Acadia Pharmaceuticals, up from $23.6 million in the prior quarter.
  • Over the last five years, Receivables - Other for ACAD hit a ceiling of $26.8 million in Q4 2025 and a floor of $403000.0 in Q3 2022.
  • Median Receivables - Other over the past 5 years was $3.2 million (2023), compared with a mean of $6.0 million.
  • Biggest five-year swings in Receivables - Other: plummeted 80.99% in 2021 and later skyrocketed 602.54% in 2024.
  • Acadia Pharmaceuticals' Receivables - Other stood at $978000.0 in 2021, then decreased by 9.51% to $885000.0 in 2022, then soared by 361.36% to $4.1 million in 2023, then soared by 45.87% to $6.0 million in 2024, then surged by 349.53% to $26.8 million in 2025.
  • The last three reported values for Receivables - Other were $26.8 million (Q4 2025), $23.6 million (Q3 2025), and $12.2 million (Q2 2025) per Business Quant data.